237 related articles for article (PubMed ID: 27158940)
1. The future of immunotherapy for sarcoma.
Tsukahara T; Emori M; Murata K; Mizushima E; Shibayama Y; Kubo T; Kanaseki T; Hirohashi Y; Yamashita T; Sato N; Torigoe T
Expert Opin Biol Ther; 2016 Aug; 16(8):1049-57. PubMed ID: 27158940
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Sarcoma: Future Horizons.
Burgess M; Gorantla V; Weiss K; Tawbi H
Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic approaches to sarcoma.
Burgess M; Tawbi H
Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy against sarcomas.
Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
[TBL] [Abstract][Full Text] [Related]
8. Current status of engineered T-cell therapy for synovial sarcoma.
Dallos M; Tap WD; D'Angelo SP
Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
[TBL] [Abstract][Full Text] [Related]
9. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
11. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Sebio A; Wilky BA; Keedy VL; Jones RL
Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
13. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
14. Promising immunotherapies for esophageal cancer.
Tanaka T; Nakamura J; Noshiro H
Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
[TBL] [Abstract][Full Text] [Related]
15. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
17. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell immunotherapy in soft tissue sarcoma.
Indelicato DJ; Finkelstein SE
Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
[TBL] [Abstract][Full Text] [Related]
19. Potential for immunotherapy in soft tissue sarcoma.
Tseng WW; Somaiah N; Engleman EG
Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
